The HDL particle number test, often called HDL-P, measures how many high-density lipoprotein particles are circulating in your blood. It is different from HDL cholesterol, which measures how much cholesterol those particles carry. That difference matters because two people can have the same HDL cholesterol level but very different numbers of HDL particles, and research suggests HDL-P may sometimes reflect cardiovascular risk more consistently than HDL cholesterol alone.
HDL particles help move cholesterol away from artery walls and back toward the liver, but they also take part in inflammation control, oxidation defense, immune signaling, and blood vessel function. A low HDL-P result usually points to reduced HDL particle availability and often appears alongside insulin resistance, high triglycerides, abdominal weight gain, type 2 diabetes, smoking, chronic inflammation, or other metabolic risk patterns. HDL-P is not a stand-alone diagnosis, but it can add useful detail when a standard lipid panel does not explain a person’s risk clearly.
- HDL-P measures HDL particle count, not HDL cholesterol content. It is usually reported in micromoles per liter, written as µmol/L.
- A common adult HDL-P target is at least 30.5 µmol/L, but some labs use sex-specific cutoffs such as over 30 µmol/L for men and over 35 µmol/L for women.
- Low HDL-P can mean higher cardiovascular risk, especially when LDL-P, ApoB, triglycerides, glucose, insulin, or inflammatory markers are also abnormal.
- Normal or high HDL cholesterol does not always mean HDL-P is optimal. Large cholesterol-rich HDL particles can raise HDL-C without increasing particle number.
- Fasting is not always required for HDL-P, but fasting may be preferred when the same blood draw includes triglycerides, LP-IR score, insulin, or glucose.
Table of Contents
- What HDL-P Measures
- HDL-P Normal Range and Result Meaning
- Low HDL-P Causes and Common Patterns
- HDL-P vs HDL Cholesterol, ApoA1, and HDL Size
- How HDL-P Fits Into Heart Risk
- Testing, Preparation, and Reliability
- How to Improve Low HDL-P and HDL Function
- Follow-Up Questions to Discuss With Your Clinician
What HDL-P Measures
HDL-P measures the concentration of HDL particles in the blood. HDL stands for high-density lipoprotein. Lipoproteins are tiny transport particles made of fat, cholesterol, phospholipids, and proteins. Their job is to move fat-like substances through watery blood.
A standard lipid panel reports HDL cholesterol, or HDL-C. That number tells you how much cholesterol is being carried inside HDL particles. HDL-P answers a different question: how many HDL particles are present.
That difference can be important. Imagine two delivery fleets. One fleet has many small vehicles carrying modest loads. Another has fewer large vehicles carrying more cargo per vehicle. Both fleets may carry the same total cargo, but the number of vehicles is different. HDL-C is more like cargo. HDL-P is more like vehicle count.
Most HDL-P testing is done as part of an advanced lipid test, especially an NMR lipoprotein profile. NMR stands for nuclear magnetic resonance, a laboratory method that estimates lipoprotein particle concentrations and sizes from the physical signals produced by particles in the sample. HDL-P may be reported with LDL particle number, small LDL-P, LDL size, HDL size, large HDL-P, VLDL-related markers, and sometimes an insulin-resistance score.
HDL particles are not all the same. They vary by size, density, protein content, lipid content, and function. Some HDL particles are small and dense. Others are larger and more cholesterol-rich. A total HDL-P result combines these HDL particles into one overall particle count, while some advanced reports break HDL into subclasses.
HDL particles are often described as “good cholesterol,” but that phrase is too simple. HDL is not cholesterol itself. It is a particle system that can help remove cholesterol from tissues, support antioxidant activity, influence inflammation, and interact with the immune system. Because HDL has several jobs, one number cannot capture everything about HDL health.
HDL-P is most useful when it adds context to other tests. It may be especially helpful when HDL cholesterol looks reassuring but other cardiometabolic markers suggest risk, or when HDL cholesterol is low and the clinician wants to understand whether the low value reflects fewer HDL particles, cholesterol-poor particles, or a broader metabolic pattern. For many people, HDL-P is ordered as part of an advanced lipid panel rather than as a single test.
HDL-P Normal Range and Result Meaning
HDL-P reference ranges vary by laboratory, assay, population, and reporting format. Many NMR-based reports use 30.5 µmol/L or higher as a general adult reference target for total HDL-P. Some lab catalogs use sex-specific adult reference values, such as greater than 30 µmol/L for men and greater than 35 µmol/L for women. Other reports use percentile-style categories.
| HDL-P result | Common interpretation | How to read it in context |
|---|---|---|
| Below about 26.7 µmol/L | Low on some percentile-based reports | Often seen with insulin resistance, high triglycerides, low HDL-C, inflammation, smoking, or higher cardiometabolic risk |
| About 26.7–30.4 µmol/L | Below median or borderline-low on many reports | May deserve attention if ApoB, LDL-P, non-HDL-C, triglycerides, glucose, or blood pressure are also abnormal |
| 30.5 µmol/L or higher | Often reported as acceptable or in range | Generally reassuring, but not protective enough to cancel out high ApoB, high LDL-P, diabetes, smoking, or strong family history |
| Above about 34.9 µmol/L | High or upper-range on some reports | Often favorable, but risk still depends on the full cardiovascular profile |
A low HDL-P result means the blood contains fewer HDL particles than expected for that lab’s reference population. It does not prove that a person has heart disease. It also does not identify a single cause. It is a risk marker, not a diagnosis.
A normal HDL-P result means your HDL particle count falls within the expected range for the test method. This is generally favorable, especially when other risk markers are also healthy. Still, a normal HDL-P does not erase the risk from high LDL particle burden, high ApoB, high blood pressure, diabetes, chronic kidney disease, smoking, or established atherosclerotic cardiovascular disease.
A high HDL-P result is usually considered favorable, but “higher” is not automatically “best” in every situation. HDL biology is complex. Very high HDL cholesterol has sometimes been linked with higher risk in observational studies, especially when HDL particles are dysfunctional or when genetic factors raise HDL-C without improving cholesterol removal. HDL-P is not the same as HDL-C, but the same caution applies: the result should be interpreted with the full clinical picture.
Units matter. Total HDL-P is commonly reported in µmol/L. Some HDL subclass results may be reported in nmol/L or as particle concentration, size, or percentage. Do not compare your number with a range from a different assay unless the units and method match.
For standard cholesterol context, HDL cholesterol is usually considered low below 40 mg/dL in men and below 50 mg/dL in women, but HDL-C and HDL-P can disagree. A person reviewing both markers may also want to compare the result with an HDL cholesterol normal range because each test describes a different part of HDL biology.
Low HDL-P Causes and Common Patterns
Low HDL-P most often appears as part of a broader metabolic pattern rather than as an isolated finding. The most common pattern is insulin resistance: higher waist circumference, higher triglycerides, lower HDL cholesterol, more small LDL particles, higher blood pressure, fatty liver tendency, and rising fasting glucose or A1c.
Insulin resistance changes the way the liver packages and exchanges fats. Triglyceride-rich particles increase, HDL particles become triglyceride-enriched, and HDL may be cleared from the blood faster. Over time, this can lower HDL-C, reduce HDL-P, shift HDL size, and raise atherogenic particle markers.
Common contributors to low HDL-P include:
- High triglycerides, especially when triglycerides are above 150 mg/dL
- Insulin resistance or type 2 diabetes
- Abdominal weight gain
- Low physical activity
- Smoking or nicotine exposure
- High intake of refined carbohydrates or added sugars
- Chronic inflammation
- Untreated hypothyroidism
- Kidney disease or significant protein loss
- Liver disease, including fatty liver
- Certain genetic lipid disorders
- Some medications, depending on the person and drug
Low HDL-P may also occur during or after acute illness. Infection, inflammation, surgery, trauma, or major stress can temporarily alter lipoprotein metabolism. In those cases, repeating the test after recovery may provide a more stable picture.
Low HDL-P often travels with low HDL cholesterol, but not always. If HDL-C is low, reviewing a low HDL cholesterol result can help identify causes that overlap with low HDL-P. If HDL-C is normal but HDL-P is low, the result may mean each HDL particle carries more cholesterol than usual, leaving fewer total particles than the HDL-C number suggests.
The most important clinical question is usually not “How do I raise HDL-P by itself?” but “What metabolic or cardiovascular risk pattern is lowering HDL-P?” For many people, the strongest clues come from triglycerides, waist size, blood pressure, fasting glucose, A1c, fasting insulin, ApoB, LDL-P, non-HDL cholesterol, liver enzymes, kidney markers, and inflammatory markers.
A low HDL-P result may deserve closer attention when it appears with any of the following:
- Triglycerides above 150 mg/dL
- HDL-C below 40 mg/dL in men or below 50 mg/dL in women
- ApoB above the person’s risk-based target
- LDL-P above range
- Non-HDL cholesterol above target
- LP-IR score above range
- Fasting glucose, A1c, or fasting insulin suggesting insulin resistance
- hs-CRP persistently elevated
- A strong family history of early heart attack or stroke
Low HDL-P by itself rarely leads directly to medication. Instead, it often prompts a closer look at the drivers of cardiometabolic risk and whether LDL-related treatment targets are strict enough for the person’s overall risk.
HDL-P vs HDL Cholesterol, ApoA1, and HDL Size
HDL-P, HDL-C, ApoA1, and HDL size are related, but they are not interchangeable. Each marker answers a different question.
| Marker | What it measures | What it can clarify |
|---|---|---|
| HDL-C | Cholesterol carried inside HDL particles | Standard lipid panel risk marker; low levels often track with metabolic risk |
| HDL-P | Number of HDL particles | Whether HDL particle count is low, normal, or high regardless of cholesterol cargo |
| ApoA1 | Main structural protein found on HDL particles | A protein-based estimate of HDL-related particle biology and HDL production |
| HDL size | Average size of HDL particles | Whether HDL particles skew smaller or larger; size alone is not a complete risk marker |
| Large HDL-P | Concentration of larger HDL particles | One HDL subclass pattern; may relate to metabolism but should not be overinterpreted alone |
HDL-C became popular because it is easy to measure and has long shown an inverse association with cardiovascular risk in population studies. Lower HDL-C often appears in people with insulin resistance, high triglycerides, obesity, type 2 diabetes, and smoking. However, drugs that raise HDL-C have not reliably reduced cardiovascular events when LDL-related risk is already treated. That finding changed how clinicians think about HDL: raising the cholesterol number is not the same as improving HDL function or reducing events.
HDL-P may sometimes track risk more consistently than HDL-C because it reflects particle count rather than cholesterol load. A person with fewer HDL particles may have less overall HDL particle surface area available for cholesterol exchange and other HDL-related functions, even if each particle is carrying a large amount of cholesterol.
ApoA1 is another HDL-related marker. ApoA1 is the main protein scaffold of HDL. Since most HDL particles contain ApoA1, a lower ApoA1 result can suggest lower HDL particle availability or impaired HDL production. Still, ApoA1 and HDL-P are not identical. ApoA1 measures protein mass, while HDL-P estimates particle concentration. If a report includes both, an ApoA1 test result can help round out the interpretation.
HDL size can be confusing. Larger HDL particles are often described as favorable, but large size is not always better. A high HDL-C level can result from large cholesterol-rich HDL particles, and that does not always mean the particles are working well. Smaller HDL particles may play important roles in cholesterol acceptance and remodeling. This is one reason total HDL-P and HDL function are often more informative than size alone.
The strongest use of HDL-P is usually in discordant results. Discordance means two related markers point in different directions. Examples include:
- HDL-C normal but HDL-P low
- HDL-C high but HDL-P only average
- HDL-C low but HDL-P near normal
- HDL-P normal but ApoB or LDL-P high
- HDL-P low with high triglycerides and high LP-IR score
In these cases, HDL-P can prevent overconfidence from a “good” HDL cholesterol number or unnecessary alarm from a low HDL-C number that needs broader context.
How HDL-P Fits Into Heart Risk
HDL-P is best used as a supporting marker in cardiovascular risk assessment. It can add useful information, but it does not replace the markers with the strongest causal and treatment-guiding role.
For atherosclerotic cardiovascular disease, the main particle burden comes from ApoB-containing lipoproteins. These include LDL, VLDL remnants, IDL, and lipoprotein(a). These particles can enter the artery wall and contribute to plaque formation. HDL particles may help with reverse cholesterol transport and vascular protection, but simply having a favorable HDL marker does not cancel out high ApoB particle burden.
That is why a low HDL-P result should usually be interpreted beside LDL-P, ApoB, LDL-C, non-HDL-C, triglycerides, Lp(a), blood pressure, glucose status, smoking status, kidney function, and personal or family history. A person with low HDL-P and high LDL-P has a different risk pattern from someone with low HDL-P but very low ApoB, normal triglycerides, normal blood pressure, and no other major risk factors.
In practical terms, HDL-P may be most helpful in these situations:
- A standard lipid panel looks “not bad,” but family history or metabolic markers suggest hidden risk.
- HDL-C is high, but there are other signs of insulin resistance or inflammation.
- HDL-C is low, and the clinician wants to know whether HDL particle count is also low.
- A patient has metabolic syndrome, type 2 diabetes, or high triglycerides.
- An advanced report already includes HDL-P along with LDL-P and LP-IR score.
- A person has residual risk despite LDL-C lowering therapy.
HDL-P should not be used to decide that LDL-related risk is harmless. If ApoB or LDL-P is high, cardiovascular risk usually follows the atherogenic particle count even when HDL-C or HDL-P looks favorable. For many prevention decisions, an ApoB blood test or an LDL particle number test carries more direct treatment weight than HDL-P.
HDL-P also overlaps with metabolic risk. Low HDL-P, high triglycerides, small LDL-P, large VLDL-P, and a high LP-IR score often point toward insulin resistance. When that pattern appears, the result is not just about cholesterol. It may signal higher future risk for type 2 diabetes, fatty liver, hypertension, and atherosclerotic disease. An LP-IR score can sometimes help connect the lipid particle pattern to insulin resistance.
Inflammation matters too. HDL particles can become less protective during chronic inflammatory states. Autoimmune disease, chronic infections, obesity-related inflammation, smoking, and poorly controlled diabetes can change HDL composition and function. In those settings, HDL quantity may not fully reflect HDL quality. A marker such as hs-CRP may help show whether inflammation is part of the broader risk picture.
A helpful way to think about HDL-P is this: low HDL-P can strengthen concern when other risk markers are abnormal, but high HDL-P should not be used as a shield against proven risks.
Testing, Preparation, and Reliability
HDL-P is usually measured from a blood sample. Many laboratories use NMR technology for particle testing. The sample may be serum or plasma, depending on the lab’s collection requirements. Some labs require a specific tube or handling method, so collection details matter.
Fasting rules depend on what else is being measured. HDL-P itself does not always require fasting, but many advanced lipid panels include triglycerides, calculated LDL-C, VLDL-related particles, LP-IR score, insulin, or glucose. These markers may be more interpretable after an 8- to 12-hour fast, especially if the goal is to compare results over time.
Ask the ordering clinician or lab whether to fast if your panel includes:
- Triglycerides
- LP-IR score
- Fasting glucose
- Fasting insulin
- Calculated LDL cholesterol
- VLDL particle measures
- A combined cardiometabolic risk panel
Temporary conditions can shift HDL-P and related markers. Results may be less stable during acute illness, after surgery, during major weight loss, during pregnancy, after a major diet change, or soon after starting or stopping lipid-related medication. When results are unexpected, repeating the test after 6 to 12 weeks of stable habits and health may be reasonable.
HDL-P also has method limitations. Different NMR platforms and lipoprotein fractionation methods may not produce identical particle counts. A result from one lab should not be treated as perfectly interchangeable with a result from another lab. When tracking change, use the same laboratory and test method when possible.
Laboratory-developed advanced lipid tests may include a caution that their clinical utility is not fully established for every measured subclass. That does not mean the test is useless. It means some markers are better supported for risk refinement than for direct treatment targets. LDL-P and ApoB usually have clearer treatment implications than HDL subclasses. HDL-P may help interpret residual and metabolic risk, but clinicians do not usually prescribe treatment to hit an HDL-P target alone.
A single HDL-P result is usually enough to add context, but trends can be helpful. If HDL-P rises while triglycerides, waist size, glucose, insulin resistance, blood pressure, ApoB, and LDL-P improve, that pattern is more meaningful than a small HDL-P change by itself.
Before testing, avoid making sudden lifestyle changes just to “pass” the test. The most useful result reflects your usual pattern. If you recently had a major infection, changed medication, started a strict diet, or lost significant weight quickly, note that timing when reviewing the result.
How to Improve Low HDL-P and HDL Function
Low HDL-P usually improves best when the underlying metabolic pattern improves. The most effective approach is not to chase HDL-P in isolation. It is to reduce insulin resistance, lower triglyceride-rich particles, improve fitness, stop smoking, improve sleep, and treat major cardiovascular risk markers.
Regular physical activity is one of the most reliable ways to improve HDL quality and overall lipid metabolism. Aerobic exercise can improve triglycerides, insulin sensitivity, blood pressure, body composition, and HDL function. Resistance training adds benefits for muscle mass and glucose control. A realistic starting plan is 150 minutes per week of moderate aerobic activity, plus two weekly strength sessions. More may be needed for weight loss or major metabolic change, but consistency matters more than a perfect plan.
Diet changes work best when they reduce triglyceride pressure and insulin resistance. Helpful patterns often include:
- Replacing sugary drinks and refined starches with higher-fiber foods
- Eating enough protein at meals to support satiety and muscle
- Choosing unsaturated fats from foods such as olive oil, nuts, seeds, avocado, and fish
- Increasing vegetables, beans, lentils, and whole-food fiber sources
- Reducing frequent desserts, white bread, pastries, and snack foods
- Limiting alcohol, especially when triglycerides are high
- Matching carbohydrate intake to activity level and glucose tolerance
Weight loss can raise HDL-related markers when excess abdominal fat and insulin resistance are present. Even a 5% to 10% body weight reduction can improve triglycerides, glucose, blood pressure, liver fat, and particle patterns in many people. The change does not need to be rapid. Slow, sustained improvement usually produces more durable results.
Smoking cessation can improve HDL function and reduce vascular injury. Smoking can damage HDL particles, increase oxidative stress, worsen inflammation, and raise cardiovascular risk through several pathways. Quitting is one of the strongest steps a person with low HDL-P can take.
Sleep and stress are often overlooked. Short sleep, untreated sleep apnea, chronic stress, and irregular schedules can worsen insulin resistance and blood pressure. For someone with low HDL-P plus high triglycerides, high glucose, or abdominal weight gain, sleep quality may be part of the metabolic picture.
Medication decisions usually focus on reducing atherogenic particle burden rather than directly raising HDL-P. Statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, omega-3 prescription products, diabetes medications, blood pressure medications, or weight-loss medications may be considered depending on the full risk profile. These choices depend on LDL-C, ApoB, LDL-P, triglycerides, diabetes status, kidney function, liver health, previous cardiovascular events, and overall risk.
Niacin can raise HDL-C, but outcome trials did not show the expected cardiovascular benefit when added to modern LDL-lowering therapy, and it can cause side effects. For that reason, raising HDL cholesterol with medication is no longer a main prevention strategy for most people. HDL-P should be improved through the broader metabolic plan rather than treated as a medication target by itself.
A sensible follow-up plan after a low HDL-P result often includes repeating the same advanced lipid test after 8 to 12 weeks of steady lifestyle changes or after a medication adjustment. The best sign is not only a higher HDL-P. A stronger improvement pattern would include lower triglycerides, lower ApoB or LDL-P if elevated, improved glucose or insulin markers, lower blood pressure, reduced waist circumference, and improved inflammatory markers when they were high.
Follow-Up Questions to Discuss With Your Clinician
A low HDL-P result is easier to use when it leads to specific follow-up questions. The goal is to connect the number to your actual cardiovascular and metabolic risk.
Useful questions include:
- Is my HDL-P low by this lab’s reference range, or only below an optimal target?
- Does my HDL-P agree or disagree with my HDL cholesterol?
- Are my triglycerides, ApoB, LDL-P, non-HDL-C, or Lp(a) more important for treatment decisions?
- Do my results suggest insulin resistance or metabolic syndrome?
- Should I check fasting insulin, A1c, glucose, liver enzymes, kidney markers, thyroid function, or hs-CRP?
- Should I repeat the test when I am fasting or after an illness has resolved?
- Is my family history strong enough to change my prevention targets?
- Would a coronary artery calcium scan or other imaging test help clarify risk?
- Which result should we track as the main treatment target?
- What change would be meaningful enough to alter my care plan?
Bring the full report, not just the HDL-P number. Advanced lipid reports often include LDL-P, small LDL-P, HDL size, large HDL-P, VLDL markers, LP-IR score, and a standard lipid panel. The pattern is usually more useful than any single marker.
It also helps to bring recent blood pressure readings, medication and supplement lists, family history details, smoking status, exercise habits, alcohol intake, and any recent illness or weight change. These details can explain why HDL-P is low and which next step is most likely to help.
Seek urgent care for symptoms that suggest a possible heart attack or stroke, regardless of HDL-P. These include chest pressure, shortness of breath, pain radiating to the arm or jaw, sudden weakness or numbness on one side, trouble speaking, fainting, or severe unexplained symptoms. HDL-P is a long-term risk marker, not an emergency test.
For most people, the most useful response to low HDL-P is calm and systematic: identify the risk pattern, treat the strongest drivers first, and repeat testing only when the result will change the plan.
References
- Quantification of HDL particle number (HDL-P) by proton NMR: Don’t believe the numbers 2024 (Review)
- High-Density Lipoprotein Particle Concentration and Size Predict Incident Coronary Artery Disease Events in a Cohort With Type 1 Diabetes 2024 (Cohort Study)
- The Role of High-Density Lipoprotein Cholesterol in 2022 2022 (Review)
- High density lipoprotein: When to rethink too much of a good thing 2023 (Review)
- The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review 2023 (Review)
- HDL-P, Total 2026 (Test Information)
Disclaimer
HDL-P results should be interpreted with your full lipid panel, medical history, medications, family history, and overall cardiovascular risk. A low or high HDL-P result does not diagnose heart disease by itself and should not be used to start, stop, or change treatment without a qualified clinician. Seek urgent medical care for symptoms of a possible heart attack or stroke, even if previous cholesterol or HDL-P results were normal.
